oxytocin and Subarachnoid-Hemorrhage

oxytocin has been researched along with Subarachnoid-Hemorrhage* in 6 studies

Reviews

1 review(s) available for oxytocin and Subarachnoid-Hemorrhage

ArticleYear
Insights into non-classic and emerging causes of hypopituitarism.
    Nature reviews. Endocrinology, 2021, Volume: 17, Issue:2

    Hypopituitarism is defined as one or more partial or complete pituitary hormone deficiencies, which are related to the anterior and/or posterior gland and can have an onset in childhood or adulthood. The most common aetiology is a sellar or suprasellar lesion, often an adenoma, which causes hypopituitarism due to tumour mass effects, or the effects of surgery and/or radiation therapy. However, other clinical conditions, such as traumatic brain injury, and autoimmune and inflammatory diseases, can result in hypopituitarism, and there are also genetic causes of hypopituitarism. Furthermore, the use of immune checkpoint inhibitors to treat cancer is increasing the risk of hypopituitarism, with a pattern of hormone defects that is different from the classic patterns and depends on mechanisms that are specific for each drug. Moreover, autoantibody production against the pituitary and hypothalamus has been demonstrated in studies investigating the development or worsening of some cases of hypopituitarism. Finally, evidence suggests that posterior pituitary damage can affect oxytocin secretion. The aim of this Review is to summarize current knowledge on non-classic and emerging causes of hypopituitarism, so as to help clinicians improve early identification, avoid life-threatening events and improve the clinical care and quality of life of patients at risk of hypopituitarism.

    Topics: Adenoma; Adrenocorticotropic Hormone; Autoimmune Hypophysitis; Brain Injuries, Traumatic; Dwarfism, Pituitary; Empty Sella Syndrome; Endocrine System Diseases; Genetic Diseases, Inborn; Humans; Hypoglycemia; Hypogonadism; Hypophysitis; Hypopituitarism; Hypothyroidism; Immune Checkpoint Inhibitors; Oxytocin; Pituitary Apoplexy; Pituitary Neoplasms; Subarachnoid Hemorrhage

2021

Other Studies

5 other study(ies) available for oxytocin and Subarachnoid-Hemorrhage

ArticleYear
Vasopressin and oxytocin in CSF and plasma of patients with aneurysmal subarachnoid haemorrhage.
    Neuropeptides, 2014, Volume: 48, Issue:2

    Clinicopathological studies on patients succumbing to subarachnoid haemorrhage (SAH) demonstrated hypothalamic lesions. The implication of the hypothalamic neuropeptides arginine-vasopressin (AVP) and oxytocin (OXT) has not been linked to aneurysmal SAH yet. This study investigates AVP and OXT in CSF and plasma of patients with spontaneous aneurysmal SAH and their association with outcome.. CSF and plasma samples of 12 patients with aneurysmal SAH were prospectively studied for 2weeks. AVP and OXT were measured by radioimmunoassay. Outcome was assessed on Glasgow-Outcome-Scale. Twenty-nine patients without neuropsychiatric disturbances served as controls. Differences in neuropeptide concentration time courses were assessed by regression models. Group comparisons were performed by Kruskal-Wallis and correlations by Spearman tests.. Regression of CSF levels between patients with poor and good outcome revealed significantly lower levels of AVP in patients with poor outcome (p=0.012) while OXT showed a trend towards lower levels (p=0.063). In plasma, no significant differences between outcome groups were found. Group comparisons between poor outcome patients and controls revealed significant differences in CSF for AVP (p=0.001) and OXT (p=0.015). In plasma, AVP yielded significantly different results while OXT did not. No differences were found between the good outcome group and controls. Plasma and CSF concentrations showed no significant correlation.. Patients with poor outcome after aneurysmal SAH have lower AVP and OXT levels in CSF than patients with good outcome while neuropeptide levels in plasma failed to reflect differences in outcome. The data indicate hypothalamic damage as an aetiologic factor for outcome after aneurysmal SAH.

    Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Female; Glasgow Outcome Scale; Humans; Hypothalamus; Male; Middle Aged; Oxytocin; Prognosis; Regression Analysis; Subarachnoid Hemorrhage; Vasopressins; Young Adult

2014
Enhanced reactivity to vasopressin in rat basilar arteries during vasospasm after subarachnoid hemorrhage.
    European journal of pharmacology, 2005, Apr-18, Volume: 513, Issue:1-2

    Subarachnoid hemorrhage increases the plasma level of vasopressin, a well-known vasoconstrictor. We examined the sensitivity to vasopressin in rat basilar artery after subarachnoid hemorrhage using a rat subarachnoid hemorrhage model. Vasospasm was observed 1-2 days after subarachnoid hemorrhage induction, and the contractile response to vasopressin in rat basilar arteries was assessed. The concentration-response curve for vasopressin in subarachnoid hemorrhage (1 day) rats shifted leftward compared with that of control rats. The concentration-response curve for vasopressin V(1) receptor agonist also shifted leftward and upward compared with that of control rats. The concentration-response curve for vasopressin was inhibited not by vasopressin V(2) receptor antagonist but by vasopressin V(1) receptor antagonist. Thus, it was demonstrated that the vasoconstricting effect of vasopressin was significantly enhanced in the vasospasm phase after subarachnoid hemorrhage.

    Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Basilar Artery; Dose-Response Relationship, Drug; Endothelium, Vascular; In Vitro Techniques; Male; Morpholines; Oxytocin; Potassium Chloride; Rats; Rats, Sprague-Dawley; Receptors, Vasopressin; Spiro Compounds; Subarachnoid Hemorrhage; Time Factors; Vasoconstriction; Vasoconstrictor Agents; Vasopressins; Vasospasm, Intracranial

2005
Hypothalamic neuropeptide release after experimental subarachnoid hemorrhage: in vivo microdialysis study.
    Acta neurologica Scandinavica, 2004, Volume: 109, Issue:5

    As evidence exists about independent regulation of peripheral and central release of the vasoactive and natriuretic neuropeptides arginine-vasopressin (AVP) and oxytocin (OXT), we investigated their release patterns following subarachnoid hemorrhage (SAH).. After injection of 0.1 ml arterial blood or saline into the great cistern of 33 Wistar rats, AVP and OXT levels were measured in blood and by microdialysis in the hypothalamic supraoptic (SON) and paraventricular nucleus (PVN). For statistical analysis, the analysis of variance (ANOVA) was used with Tukey HSD post hoc ANOVA tests to determine specific group differences.. Plasma AVP and OXT peaked 2 h after SAH (P < 0.05), and normalized at 4 h. In the SON, both AVP and OXT peaked 4 h after SAH (P < 0.05). In the PVN, AVP increased in both groups (P < 0.05), while no OXT release occurred. By the sham group, any effect of experimental procedure was excluded.. The SAH-specific central neuropeptide release, which exceeded peripheral release and continued longer, may contribute to pathophysiological events following SAH.

    Topics: Animals; Arginine Vasopressin; Hypothalamus; Male; Neuropeptides; Oxytocin; Paraventricular Hypothalamic Nucleus; Rats; Rats, Wistar; Subarachnoid Hemorrhage; Supraoptic Nucleus

2004
Effects of vasopressin and oxytocin on canine cerebral circulation in vivo.
    Journal of neurosurgery, 1992, Volume: 77, Issue:3

    In vivo experiments on the vasoactive effects of vasopressin and oxytocin on cerebral circulation were carried out in anesthetized dogs, using an electromagnetic flowmeter to measure vertebral blood flow and angiography to measure the internal diameter of the basilar artery. Direct bolus infusion of 1 pmol to 1 nmol of vasopressin or 10 pmol to 10 nmol of oxytocin into a femoral-vertebral artery shunt produced a dose-dependent decrease in vertebral artery blood flow without significantly affecting mean arterial blood pressure. Vasopressin was more potent than endothelin and neuropeptide Y, which have also been demonstrated to induce long-lasting decreases in vertebral artery blood flow. However, direct bolus infusion of vasopressin (100 pmol and 1 nmol) or oxytocin (1 nmol and 10 nmol) into the vertebral artery dilated major vessels including the vertebral, anterior spinal, and basilar arteries, as well as the circle of Willis and its main branches, while endothelin (1 nmol) and neuropeptide Y (5 nmol) caused no change in the diameters of major cerebral arteries. The V1 antagonist d(CH2)5tyrosine(methyl) arginine vasopressin suppressed the effects of both vasopressin and oxytocin. Vasopressin was over 10 times as potent as oxytocin in both assays. The vasodilatory effect of vasopressin, which may be mediated by an endothelium-dependent mechanism, was functionally damaged in dogs after experimental subarachnoid hemorrhage. These data suggest regional differences in the sensitivity and responsiveness of vasculature to vasopressin and oxytocin, and specifically that both peptides act through V1 receptors to decrease the resistance of large vessels and increase the resistance of small vessels.

    Topics: Animals; Basilar Artery; Cerebral Angiography; Cerebrovascular Circulation; Dogs; Dose-Response Relationship, Drug; Oxytocin; Subarachnoid Hemorrhage; Vasoconstriction; Vasodilation; Vasopressins; Vertebral Artery

1992
Subarachnoid haemorrhage mimicking acute water intoxication during labour augmented by oxytocin infusion.
    The British journal of clinical practice, 1990, Volume: 44, Issue:12

    Topics: Acute Disease; Adult; Diagnosis, Differential; Female; Humans; Obstetric Labor Complications; Oxytocin; Pregnancy; Pregnancy Complications, Cardiovascular; Subarachnoid Hemorrhage; Water Intoxication

1990